Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma

Published:2024-06 Issue: Volume:204 Page:114048
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Carril-Ajuria Lucia,Lavaud Pernelle,Dalban Cecile,Negrier Sylvie,Gravis Gwénaëlle,Motzer Robert J.,Chevreau Christine,Tannir Nizar M.,Oudard Stéphane,McDermott David F.,Laguerre Brigitte,Hammers Hans J.,Barthelemy Philippe,Plimack Elizabeth R.,Borchiellini Delphine,Gross-Goupil Marine,Jiang Ruiyun,Lee Chung-Wei,de Silva Heshani,Rini Brian I.,Escudier Bernard,Albigès Laurence

Funder

Bristol-Myers Squibb

Unicancer

Publisher

Elsevier BV

Reference31 articles.

1. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

2. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

3. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma;Choueiri;N Engl J Med,2021

4. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma;Motzer;N Engl J Med,2021

5. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Escudier;Ann Oncol,2019

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma;European Journal of Cancer;2024-07

2. Multi-Omics Reveals Tumor Cell Heterogeneity Effects on the Immunosuppression in ccRCC and Facilitates Prognostic Model Construction;2024